Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

EOLS earnings analysis

Filed May 4, 2026 · Our reading of the company's report

The latest report

Evolus, Inc. reported a net revenue of $73.1 million for Q1 2026, a 6.7% increase from $68.5 million in Q1 2025, primarily driven by the launch of its Evolysse® product line. However, the company faced a net loss of…

Read full summary

Evolus, Inc. reported a net revenue of $73.1 million for Q1 2026, a 6.7% increase from $68.5 million in Q1 2025, primarily driven by the launch of its Evolysse® product line. However, the company faced a net loss of $10.7 million, less than the $18.9 million loss from the previous year, reflecting improved operating efficiency. The gross profit margin decreased slightly from 68.1% to 66.9% year-over-year, amid rising costs.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.16
Gross margin
66.9%
Segment
Jeuveau®
Segment
Evolysse®

What stood out

  • Revenue Growth

    Total revenue increased by 6.7% to $73.1 million compared to $68.5 million in Q1 2025.

  • Reduced Losses

    Net loss decreased to $10.7 million in Q1 2026 from $18.9 million in the same quarter last year.

  • Segment Performance

    Product revenue grew from $68.1 million to $72.7 million, contributing significantly to overall revenue.

  • Improved Cash Flow

    Cash used in operating activities decreased to $10 million from $15.6 million year-over-year.

  • Debt Management

    Entered a $30 million revolving credit facility to manage cash flow, providing financial flexibility.

  • Cost Reduction Efforts

    Selling, general and administrative expenses decreased by 8.2% to $52.0 million from $56.6 million.

What to watch

  • High Accumulated Deficit

    Accumulated deficit reached $671.7 million as of March 31, 2026, limiting future operational flexibility.

  • Regulatory Risks

    Potential changes in trade tariffs could adversely impact product import costs and consumer sentiment.

  • Product Development Dependence

    Dependence on Symatese for regulatory approval of the Evolysse® product line poses a risk to future revenues.

Management's outlook

Outlook deferred to next earnings press release.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.